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Abstract
Enterotoxigenic Escherichia coli (ETEC) is an endemic health threat in underdeveloped
nations. Despite the significant effort extended to vaccine trials using ETEC colonization
factors, these approaches have generally not been especially effective in mediating cross-
protective immunity. We used quantitative proteomics to identify 24 proteins that differed in
abundance in membrane protein preparations derived from wild-type vs. a type II secretion
system mutant of ETEC. We expressed and purified a subset of these proteins and identi-
fied nine antigens that generated significant immune responses in mice. Sera from mice
immunized with either the MltA-interacting protein MipA, the periplasmic chaperone seven-
teen kilodalton protein, Skp, or a long-chain fatty acid outer membrane transporter,
ETEC_2479, reduced the adherence of multiple ETEC strains differing in colonization factor
expression to human intestinal epithelial cells. In intranasal challenge assays of mice,
immunization with ETEC_2479 protected 88% of mice from an otherwise lethal challenge
with ETEC H10407. Immunization with either Skp or MipA provided an intermediate degree
of protection, 68 and 64%, respectively. Protection was significantly correlated with the
induction of a secretory immunoglobulin A response. This study has identified several pro-
teins that are conserved among heterologous ETEC strains and may thus potentially
improve cross-protective efficacy if incorporated into future vaccine designs.
Author Summary
Diarrheal disease is an endemic health threat in underdeveloped nations. One of the major
causative agents of diarrheal disease is a group of bacteria collectively known as enterotoxi-
genic Escherichia coli (ETEC). These organisms can cause disease symptoms ranging from
mild diarrhea to a more severe, cholera-like form. We were interested in characterizing
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ETEC proteins that can generate a protective immune response as the first step in identify-
ing potential new vaccine candidates. We used proteomics to identify a subset of ETEC
proteins and then characterized this subset for their ability to inhibit ETEC binding to cul-
tured intestinal epithelial cells. We then vaccinated mice with the most promising antigen
candidates and were able to identify three proteins that protected mice from clinical signs
of disease normally caused by ETEC infection. We suggest that future characterization of
these proteins may potentially improve our collective efforts to create safe, effective, and
broadly protective ETEC vaccines.
Introduction
Enterotoxigenic Escherichia coli (ETEC) is a significant cause of human morbidity due to infec-
tious diarrhea and resultant malnutrition [1]. A recent Global Enteric Multicenter study con-
ducted over a 3-year period to identify the etiology of pediatric diarrheal diseases in sub-
Saharan Africa and South Asia found that ETEC infection led to moderate to severe diarrhea in
60–70% of ETEC infected patients and found that ETEC was present at all study sites [2].
ETEC are a diverse group of pathogens that colonize the small intestine, where they attach
to mucosal surfaces using surface antigens known as colonization factors [CFs; [3]. ETEC
infections are associated with an acute watery diarrhea that can lead to rapid dehydration [1].
At least 25 unique CFs have been identified [4]. ETEC strains also express heat-labile (LT) and/
or heat-stable (ST) enterotoxins [5]. The enzymatic activities of these enterotoxins cause diar-
rhea by ultimately inducing water and electrolyte loss from the intestine of infected subjects
[5].
Several strategies have been used for ETEC vaccine development. Purified CFs have been
used as oral immunogens to provide protection against later challenge with ETEC expressing
homologous CFs [6]. A commonly used approach has involved using the cholera toxin B sub-
unit (CT-B) with formalin-inactivated ETEC strains expressing the most prevalent CFs [7].
This approach showed that the vaccine elicited IgA responses against the different CFs that
were used [6]. However, further trials based on this approach with vaccines expressing CFA/I,
CS1-3, CS5, and a recombinant CT-B suggested the need to improve vaccine safety in infants
and young children [8,9]. A new version of this oral vaccine with an increased level of CF
expression is being tested [10].
An approach with a live attenuated oral ETEC vaccine was also taken where an ETEC vari-
ant (E1392/75-2A) that had lost the capacity to produce toxin but still expressed CFA/II was
used for oral vaccination. The vaccination showed 75% protection against ETEC expressing
CFA/II [11]. E1392/75-2A was further attenuated and found to be immunogenic and safe to
administer to humans [11]. However, challenge studies have, to our knowledge, not been con-
ducted to determine protective efficacy. A recent study combined six ETEC vaccine strains
expressing different CFs with the LT B subunit [12]. This vaccine formulation (ACE527),
which was used in a phase I trial [12], was well tolerated and immunogenic [13,14] and may be
the subject of future development.
An attenuated S. flexneri 2a vaccine strain CVD 1204, bearing deletions in the guanine
nucleotide biosynthetic pathway (ΔguaBA), was used to express different ETEC colonization
factors along with mutated forms of LT (LThK63 or LThR72); [15]). Following intranasal
immunization of guinea pigs, both serum IgG and mucosal IgA responses against the CFs were
detected. However, the immune response was not consistent against the mutant LT [16]. This
approach was improved upon by using four different ETEC fimbrial antigens (CFA/I, CS2,
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CS3, and CS4) and LThk63 expressed separately in CVD 1204 [17]. However, the invasive
capacity of S. flexneri ΔguaBA was significantly reduced, which may limit its ability to stimulate
robust immune responses [18], and expression of ETEC CFs further reduces its invasiveness
[19]. An invasive strain, S. flexneri 2a (SC608) was also developed for heterologous antigen
expression [20]. All these studies showed a significant immune response against ETEC CFs.
However, none of these immunization studies were, to our knowledge, followed with ETEC
challenge, due to lack of a proper animal model to assess directly protection against ETEC
infection.
Plasmid-based antigens such as EtpA and EatA have protective efficacy against ETEC chal-
lenge in a mouse model [4]. EtpA is secreted by a two-partner secretion system and functions
as an ETEC adhesin that promotes colonization of mice [21]. Immunization with recombinant
EtpA provided protection against ETEC H10407 challenge, based upon reduced ETEC coloni-
zation of the mouse intestine [21]. EatA is a serine protease that degrades EtpA [22]. EatA also
degrades MUC2, a major component of intestinal mucin [23]. The EatA passenger domain is
immunogenic and protective against ETEC infection of mice [23]. The eatA gene was present
in ~70% of ETEC strains collected from Chile and Guinea Bissau [23].
Other proteins under investigation for their potential to be used in ETEC vaccines are the
YghJ metalloprotease and EaeH, a putative adhesin [4]. YghJ degrades MUC2 and antibodies
raised against YghJ inhibit LT delivery [24]. EaeH has immunoglobulin-like domains which
are similar to domains of other proteins involved in adhesion [4]. Further studies are needed to
realize the full potential of these proteins as vaccine candidates. Genes involved in the biogene-
sis of Type I fimbriae in ETEC are upregulated in their expression upon contact with epithelial
cells [25]. Type I fimbriae were used as a vaccine candidate in pigs and significantly reduced
the intestinal load of ETEC [26]. It may be possible to use highly conserved subunits of Type I
fimbriae as potential vaccine candidates [4].
A major challenge to ETEC vaccine development lies in the genomic diversity of the strains
[27]. Ultimately, it may be desirable to identify antigens that are sufficiently conserved to pro-
vide a broad range of protection against the diverse population of ETEC strains that cause diar-
rheal disease [4]. ETEC protective antigens remain relatively poorly defined in comparison
with studies of other diarrheal pathogens. Indeed, with the exception of antibody responses to
LT and CFs, relatively little is known about the human immune response to ETEC infection.
Genome sequence data are now available for several ETEC isolates that have previously been
studied in human vaccine trials. These data suggest that the genomes of these organisms are
variable [27]. The apparent sequence diversity among strains suggests that identifying broadly
conserved antigens with a “reverse vaccinology” approach [28], rather than focusing on a lim-
ited class of proteins (i.e. CFs) may be an effective strategy for vaccine development.
Bacterial surface proteins are attractive as targets as vaccine components [29]. However,
identifying these proteins can be difficult, and in the past has typically required using chro-
matographic separation methods [30] susceptible to contamination [31]. ETEC utilizes a type
II secretion system (T2SS) to transport proteins from the cytoplasm to the outer membrane
[32]. While the substrates of the T2SS are incompletely characterized, we hypothesized that at
least a subset of these proteins may be effective vaccine components. In the current study, we
identified several ETEC proteins that differed in their abundance in membrane protein prepa-
rations from wild-type (WT) vs. a type II secretion mutant of ETEC. After purifying these pro-
teins, we generated antisera and characterized the ability of these antisera to protect cultured
intestinal epithelial cells from adherence by a diverse panel of ETEC strains differing in CF
type. We also identified three ETEC proteins that provide protective immunity in an intranasal
mouse challenge model.
Protective ETEC Antigens
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Methods
Ethics statement
The Kansas State University Institutional Animal Care and Use Committee approved the ani-
mal procedures (IACUC protocol #3196) in the context of the Kansas State University Animal
Welfare Assurance Number A3609-01, in compliance with the Public Health Service (PHS)
Policy on Humane Care and Use of Laboratory Animals.
Bacterial strains
The ETEC strains used are described in Table 1. ETEC H10407 was originally isolated from a
patient with a severe cholera-like diarrhea in Bangladesh [33].
The ETEC H10407 ΔgspEmutant was a gift from Dr. James M. Fleckenstein [21]. ETEC
strains used for in vitro adherence assays were gifts from Dr. Stephen Savarino. Deletion
mutants in the skp,mipA, and ETEC_2479 genes were generated using the λ-Red recombinase
method [46]. Mutants were confirmed by both PCR screening and DNA sequencing. ETEC
were plated on colonization factor antigen (CFA) agar plates (1% Casamino acids, 0.15% yeast
extract, 2% agar, 0.4 mMmagnesium sulfate, 0.04 mMmanganese chloride) and grown at
37°C. For adherence assays, individual colonies were inoculated in Luria-Bertani (LB) broth
overnight followed by re-inoculation of overnight cultures in Eagle’s minimal essential medium
(EMEM) to an OD600 of 0.6.
Bacterial fractionation and mass spectrometry
Cytoplasmic and membrane protein fractions were obtained by growing WT and ΔgspE
mutant ETEC H10407 strains overnight in 50 ml CAYE media (2% Casamino acids, 0.6% yeast
Table 1. ETEC strains used in this study.
Strain CF type Serotype Location Source/Reference





B7A CS6 O148:H28 Vietnam [35]
E24377A CS1,CS3 O139:H28 Egypt [36]
278485–1 CS2,CS3 O6:H16 Bangladesh [37]
M421C1 CS5,CS6 SA:K83:H- Morocco [38]
2–1 CS6 O159:NM Saudi Arabia [39]
WS6866B CS8 O25:H- Egypt [40]
2230 CS10 025:H16 Senegal [41]
350C1A CS12 O159:H4 Kenya [38]
PE360 CS13 O9:H- Australia [42]
E7476A CS14 O166:H27 South Africa [43]
E20738A CS17 O114:H21 Zaire [44]
ARG-2 CS18 O20:K27:H- Argentina [45]
DS26-1 CS19 O8:H9 Saudi Arabia [39]
WS2173A CS23 O71:H4 Egypt S. Savarino
WS4264A-1 CS25 O64:H- Egypt S. Savarino
WS7162A-1 CS27 O15:H40 Egypt S. Savarino
doi:10.1371/journal.pntd.0003924.t001
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extract, 43 mM NaCl, 38 mM K2HPO4, 0.25% glucose, 0.1% trace minerals). Bacterial cultures
were centrifuged, washed in PBS, and then treated with lysozyme and recentrifuged. The pellet
was resuspended in 10 mM Tris-HCl, pH 7.0, sonicated, and centrifuged. The supernatant was
subjected to ultracentrifugation (1 h, 50,000 g, 4°C), after which the supernatant was retained
as the cytoplasmic fraction. The pellet was resuspended in 10 mM Tris-HCl, pH 7.0 and
retained as the membrane fraction. Equal amounts of protein from each fraction (~50 μg) were
digested to peptides with trypsin, differentially labeled with light- and heavy-isotopologs of
formaldehyde (Cambridge Isotope Labs), combined, resolved by isoelectric focusing, and ana-
lyzed by nLC-MS/MS using an LTQ-Orbitrap mass spectrometer. The Mascot search engine
was used to compare the measured fragment spectra against an in silico translation of the
ETEC H10407 genome.
Antigen cloning, expression, and purification
PCR primers were designed so as to amplify genes without predicted signal-peptide coding
sequences. PCR products were generated from chromosomal ETEC H10407 DNA and intro-
duced into pET42a to generate recombinant proteins fused to a glutathione-S-transferase
(GST) epitope. Plasmids were transformed into E. coli BL21(DE3) cells. Bacterial cultures were
grown overnight at 37°C and subcultured 1:100 into fresh media. The subcultured cells were
grown for 2 h at 37°C until reaching an OD600 of 0.2–0.5. Isopropyl β-D-1-thiogalactopyrano-
side (IPTG; 1 mM) was added and the bacterial cultures were grown for an additional 2 h, after
which the cells were centrifuged (10 min, 10,000 g, 4°C). The cells were lysed in 1/20 culture
volume of Bugbuster Protein Extraction Reagent (Novagen), rotated for 15 min at room tem-
perature, and subjected to ultracentrifugation (1 h, 2,500 g, 4°C), after which the supernatant
was retained. Supernatants were applied to GST-Bind Resin (Novagen), incubated at 4°C over-
night with rotation, centrifuged (5 min, 1,000 g, 4°C), washed 3 times with GSTWash Buffer
(Novagen), and eluted in GST elute buffer. The GST protein was also expressed separately and
purified using similar conditions for use as an immunization control in subsequent experi-
ments. The GST tags were not removed after protein purification. Potential contamination of
antigen preparations with LPS was quantified using the Chromogenic Endotoxin Quantitation
Kit (Pierce). LPS was present at negligible quantities in antigen preparations used for immuni-
zation (less than 3 pg/dose).
Production of polyclonal antisera
Mice were immunized with 200 μg of each purified protein suspended in 50 mM Tris HCl pH
7.5, 50 mM NaCl, mixed with Complete Freund’s Adjuvant, and administered into multiple
sites subcutaneously. Booster injections were administered twice at 2-week intervals, using
200 μg of antigen mixed with Incomplete Freund’s Adjuvant. Two weeks after the final immu-
nization, the mice were euthanized, exsanguinated, and the blood was processed into serum.
Control serum was also obtained from mice treated with PBS or a GST-epitope control protein.
For each antigen, mouse sera were individually tested using ELISAs, then pooled by group, and
stored at -80°C.
Immunoassays
IgG and IgA concentrations in mouse sera and feces, respectively, were analyzed using ELISAs.
We collected blood by intracardiac puncture after sacrificing the animals after challenge. To
obtain fecal antibodies, we collected five fresh stool pellets from each animal. Stool pellets were
added to 1 ml of fecal reconstitution buffer (50 mM ethylenediaminetetraacetic acid (EDTA),
0.1 mg/ml soybean trypsin inhibitor, 1.39 μg/ml phenylmethylsulfonylfluoride (PMSF), and
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homogenized. The samples were centrifuged (5 min, 5,000 g) to remove insoluble material and
the supernatants were stored at -80°C.
ELISAs were performed in polystyrene 96-well, flat bottom plates (Whatman) coated with
0.5 μg/ml of each purified protein or BSA and incubated overnight at 4°C. Plates were washed
3X in PBS, 0.1% Tween-20 and blocked with 5% milk in PBS, 0.1% Tween-20 for 1 h at room
temperature. For serum IgG analysis, 50 μl of each serum sample was added in duplicate to
antigen-coated wells and incubated at 37°C for 1 h. Goat anti-mouse Ig (H+L) HRP detection
antibody (Southern Biotech) diluted 1:4,000 in 0.1% PBS-Tween was added to the wells and
incubated 37°C for 30 min. Plates were developed with 1-StepTM Ultra TMB-ELISA (Thermo)
and quenched with 3 N H2SO4. Absorbance was read at 450 nm. Antibody titers were trans-
formed logarithmically and the Student’s t test was used to compare the mean serum antibody
titer values of different groups of mice with those of non-immunized mice. Differences in P val-
ues of< 0.05 were considered significant. For fecal IgA analysis, 50 μl of fecal supernatants
were used with a rabbit anti-mouse IgA HRP detection antibody (Sigma) and developed as
described above.
In vitro adherence assays
HCT-8 cells (5104 cells/well) were grown in 24-well plates and incubated for 16 h in EMEM.
We added serial dilutions (5 μg/ml to 500 pg/ml) of antisera prepared against ETEC antigens
or control sera from non-immunized mice, followed by 5105 colony-forming units (CFUs) of
ETEC strains that are diverse in CF-type (Table 1). HCT-8 cells were incubated with ETEC for
1 h at 37°C. Following incubation, cells were washed three times with sterile PBS to remove
unbound ETEC and then lysed in 1% saponin. Cell lysates were serially diluted and plated for
enumeration of adherent bacteria. We calculated the number of bacteria that remained cell-
associated, relative to the bacterial inocula and computed the % reduction in adherence result-
ing from serum-containing polyclonal antibodies raised against ETEC proteins vs. serum from
non-immunized mice. We compared the data statistically using paired Student’s t tests and
considered p-values< 0.05 significant.
Intranasal challenge assays
Female BALB/c mice (15/group) were obtained from the Jackson Laboratory (Bar Harbor,
Maine). Mice were housed in microisolator cages and provided with food and water ad libitum.
Antigens were administered intranasally at 20 μg/dose by mixing ETEC proteins with 2.5 μg of
cholera toxin (Sigma-Aldrich) in 25 μl PBS to the external nares of mice lightly anesthetized
with isoflurane. Booster doses were administered 2- and 4-weeks after the initial vaccination.
Intranasal challenge studies were conducted as previously described [47, 48], with minor
modifications. Two weeks after the final immunization, the mice were lightly anesthetized
with isoflurane in a VetEquip RC2 isoflurane anesthesia machine and challenged intranasally
with 5108 CFUs of ETEC H10407. To quantify changes to mouse clinical signs of illness as
a function of ETEC challenge and immunization, we observed mice every 4 h after challenge
and recorded the clinical signs of illness (lack of responsiveness to stimulation, hunched
posture, ruffled hair coat, dehydration) as a function of time. Data were analyzed statistically
using log-rank tests. If mice displayed clinical signs of illness, or at the end of the study
(7 d), they were euthanized, necropsied, and their lungs were removed aseptically. Lungs
were homogenized, serially diluted in PBS, and plated on MacConkey agar to enumerate
ETEC.
Protective ETEC Antigens
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003924 August 5, 2015 6 / 16
Results
Antigen selection, purification, and serum IgG responses
We compared the relative abundance of proteins from membrane protein preparations
between WT ETEC H10407 and an isogenic strain deficient in T2SS function (ΔgspE) using a
mass spectrometry-based approach. GspE provides an ATP hydrolysis-dependent conforma-
tional change to the T2SS that drives protein secretion [49]. We isolated proteins fromWT and
ΔgspE ETEC and fractionated the bacterial proteins to cytoplasmic, secreted, and membrane
fractions. We digested proteins with trypsin and differentially labeled the peptides with isoto-
pologs of formaldehyde. We mixed equal quantities of protein from each sample and resolved
them by in-solution isoelectric focusing (IEF). IEF fractions were further analyzed by nLC-MS/
MS using an LTQ-Orbitrap mass spectrometer. We used the Mascot search engine to compare
the measured fragment spectra against an in silico translation of the ETEC H10407 genome.
We computed the relative abundance ratios of the proteins that were isolated and identified
from both WT and ΔgspE ETEC. We identified 402 proteins from 1,901 sequenced peptides
and refined this list to 24 proteins that were enriched in the membrane fractions of WT, but
not ΔgspE ETEC. Our analysis revealed several membrane proteins, flagellar subunits, and
putative invasins (Table 2).
Of these 24 ETEC proteins identified, we cloned, expressed, and purified 9 antigens for fur-
ther characterization, primarily based upon the solubility of recombinant forms of the proteins.
Table 2. ETEC H10407 proteins enriched in membrane protein preparations fromWT vs.ΔgspE.
ETEC antigen % AA identity to nearest E. coli K-12
match
CcmA, ATP-binding component of ABC transporter 100% over 205 AAs
ClpX, ATP-dependent Clp protease ATP-binding subunit 100% over 424 AAs
DLP12 prophage; truncated outer membrane porin 100% over 127 AAs
Dps, DNA starvation/stationary phase protection protein 100% over 167 AAs
EngA, GTP-binding protein 100% over 490 AAs
ETEC_2479, long-chain fatty acid outer membrane
transporter
100% over 448 AAs
FabD, acyl carrier protein S-malonyltransferase 31% over 109 AAs
FlgE, ﬂagellar hook protein 100% over 402 AAs
FliC, ﬂagellin 52% over 543 AAs
MipA, MltA-interacting protein 99% over 248 AAs
LepA, GTP-binding protein 94% over 608 AAs
OmpA, outer membrane protein A 99% over 346 AAs
OmpR, osmolarity response regulator 38% over 239 AAs
OmpW, outer membrane protein W 100% over 212 AAs
OmpX, outer membrane protein X 100% over 171 AAs
Outer membrane porin protein C 100% over 367 AAs
Pbp5, penicillin-binding protein 5 100% over 403 AAs
Peptidyl-propyl cis-trans isomerase 32% over 146 AAs
Skp, periplasmic chaperone 99% over 161 AAs
Slp, outer membrane protein 99% over 188 AAs
SmpB, SsrA-binding protein 100% over 151 AAs
TibA, adhesin/invasin 33% over 942 AAs
TolC, outer membrane protein 100% over 493 AAs
UP12, universal stress protein UP12 100% over 142 AAs
doi:10.1371/journal.pntd.0003924.t002
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We amplified the genes encoding the identified proteins in such a way to exclude predicted sig-
nal-peptides. PCR products were generated from chromosomal ETEC H10407 DNA and
cloned as fusions to glutathione-S-transferase (GST). These plasmids were expressed in E. coli
BL21(DE3) and GST-recombinant proteins were purified using GST-Bind Resin (Fig 1A). We
used ELISAs to quantify antibody titers in pooled mouse sera. The IgG responses were variable,
with the FlgE flagellar hook protein, yielding a 560-fold response (Fig 1B). Other antigens
induced a 3- to 85-fold increase in IgG concentrations (Fig 1B). Several other proteins were not
studied further in the context of this work, as they were partitioned into inclusion bodies and
not easily maintained in a soluble form. It is conceivable that their fusion to other epitope tags
or their purification in the presence of urea might overcome these challenges in future studies.
Adherence assays
We quantified the extent to which the mouse antisera would subsequently protect against
ETEC H10407 adherence to HCT-8 cells. Of the 9 antigens tested, 3 antigens (Skp, MipA, and
Fig 1. Antigen selection, purification, and serum IgG responses. A. Purification of ETEC antigens
identified after bacterial fractionation and mass spectrometry. Top panel, induction in E. coli BL21 (DE3) cells;
bottom panel, purification over glutathione S-transferase (GST) resin.B. Serum IgG responses in mice. Data
are plotted as the fold-change in serum IgG after immunization with the indicated antigens, n = 3/group.
doi:10.1371/journal.pntd.0003924.g001
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ETEC_2479) showed a significant ability to inhibit H10407 adherence (Fig 2A). To determine
the specificity of these antisera for their respective antigens, we deleted individually the genes
encoding Skp, MipA, and ETEC_2479 and then re-evaluated the ability of the respective anti-
sera to protect against the adherence of these ETEC mutants to HCT-8 cells. The antisera
inhibited the WT strain and the 2 heterologous ETEC mutants, but no longer inhibited the
adherence of the corresponding homologous ETEC mutant to as great an extent, suggesting
that the phenotypes observed are largely attributable to antisera specificity (Fig 2B).
Fig 2. Adherence assays. A. Adherence of ETEC H10407 to HCT-8 cells in the presence of antisera. The
fold-change in ETEC H10407 adherence is plotted as a function of incubation with the indicated antisera,
after normalization to control samples. Asterisks indicate the antisera showing significant protection against
ETEC H10407 that were selected for further characterization, n = 3/group.B. Analysis of antisera specificity.
Deletion mutants were constructed for the skp,mipA, and ETEC_2479 genes and then analyzed for their
adherence to HCT-8 cells in the presence of the indicated antisera. Asterisks indicate significant reduction in
bacterial adherence, n = 4-12/group.C. Heat map displaying the fold-change in adherence of the indicated
ETEC strains to HCT-8 cells after their incubation with the indicated antisera. The scale ranges from 0.5 to a
10-fold decrease in adherence, as compared with control samples, n = 3/group. Red colors depict reduced
ETEC adherence in the presence of antisera, while green colors depict increased adherence. The midpoint of
the color gradient was set as a 2-fold reduction in adherence (black).
doi:10.1371/journal.pntd.0003924.g002
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Antisera raised against Skp, MipA, and ETEC_2479 were further examined for their protec-
tive efficacy in reducing the adherence to HCT-8 cells of a panel of other ETEC strains that dif-
fer in CF-type (Table 1). Antisera raised against ETEC_2479 provided the highest degree of
protection against the panel of ETEC strains. Antisera raised against Skp protected against
most of the strains, except ETECM421C1. Antisera raised against MipA protected against
many strains, but failed to reduce the adherence of ETEC strains M421C1, 27845–1, and
E20738A (Fig 2C).
Intranasal challenges
We conducted an intranasal challenge assay to evaluate the efficacy of immunizing mice
against Skp, MipA, and ETEC_2479 in protecting mice against an otherwise lethal challenge
with ETEC H10407. Mice (22-29/group) were immunized three times at two-week intervals
with individual antigens combined with cholera toxin. Mice were inoculated intranasally with
ETEC H10407 and then evaluated for clinical signs of disease over a 7-day period. All three
antigens were protective against the infectious challenge to variable degrees (Fig 3A).
ETEC_2479 was the most effective, providing protection for 22 of 25 (88%) of the immunized
mice. Immunization with Skp or MipA yielded lesser, though still significant degrees of sur-
vival, with 17/25 (68%) and 16/25 (64%) of the mice surviving the infection. By contrast, only
2/29 (7%) of control mice treated with PBS and 2/20 (10%) of mice immunized with a GST
purification control survived longer than 76 h after infection.
We observed high loads of ETEC (~109−10 CFUs/g) in the lungs of mice that were eutha-
nized due to their presentation of clinical signs of disease (Fig 3B). By contrast, relatively little
ETEC (~103−5 CFUs/g) was cultured from the lungs of mice that survived the infection (Fig 3B,
compare open to closed symbols). ETEC loads were inversely related to the concentrations of
IgA obtained from the feces of infected mice (Fig 3C). Fecal IgA responses were highly variable,
but significantly correlated with mouse survival (Fig 3C, compare open to closed symbols).
Mice that did not develop significant fecal IgA responses against the antigens did not survive
the infectious challenge.
Fig 3. Intranasal challenge. A. Survival assay. The survival of mice is plotted as a function of time after mice were inoculated with ETEC H10407 following
immunization with the indicated antigens. Asterisks indicate significant difference in survival, log-rank test, n = 22-29/group. B. ETEC loads (CFUs/g lung) in
mice infected with ETEC H10407 at euthanasia or at the end of the study (7 d). Open symbols indicate mice that survived for the duration of the study. Closed
symbols indicate mice that were euthanized due to their display of clinical signs of illness, n = 22-29/group. C. Fold change in mouse fecal IgA
concentrations, n = 22-29/group, after inoculation with ETEC H10407 following immunization with the indicated antigens. Open symbols indicate mice that
survived for the duration of the study. Closed symbols indicate mice that were euthanized due to their display of clinical signs of illness.
doi:10.1371/journal.pntd.0003924.g003
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Discussion
Bacterial surface proteins mediate adhesion and invasion to host cells and are often important
vaccine candidates. The T2SS is considered important to ETEC virulence, as it is involved in
secretion of proteins to the bacterial surface [50, 32]. We compared the difference in abun-
dance between membrane protein preparations from ETEC H10407 strains possessing or lack-
ing a functional T2SS system. In vitro adherence studies using the antisera produced in mice
refined our study towards three antigens that showed a protective effect against bacterial adhe-
sion to host cells. Similar approaches could be used to identify ETEC OMPs that are secreted
by pathways other than the T2SS.
One limitation of our work is that many of the proteins we identified are somewhat unex-
pected and may not be entirely consistent with what might be expected from mutating the
T2SS. The molecular basis for this result is unclear. However, we evaluated only the differential
abundance of the proteins between the WT and the ΔgspEmutant and did not formally evalu-
ate the secretion of these proteins by the T2SS. We rather chose to focus on the extent to which
antibodies developed against these proteins might protect both against ETEC adherence in
vitro and in the intranasal challenge model. Studying the mechanisms by which the ETEC anti-
gens described are secreted may be interesting topics for future research.
The antigens identified in this study were effective in preventing ETEC attachment to HCT-
8 cells, as well as in reducing lethality in an ETEC infectious challenge in mice. Skp is a molecu-
lar chaperone involved in outer membrane protein biogenesis that is believed to rescue misdi-
rected OMPs [51] but may also function as a general chaperone [52]. The utility of using
chaperones as vaccine candidates has been shown with other bacteria such as Clostridium diffi-
cile [53] and Brucella melitensis [54]. In addition, previous studies have suggested that Skp may
be a component of the outer membrane [55]. MipA belongs to the MltA-interacting protein
superfamily involved in remodeling peptidoglycan. Although few studies have focused on this
protein as a vaccine candidate, it was previously identified as an ETEC immunoreactive protein
[56]. MipA of Salmonella paratyphi A has been used as a vaccine candidate with moderate pro-
tection [57]. The ETEC_2479 long chain fatty acid transporter OMP is predicted to function as
a multifunctional outer membrane porin essential for transport of long chain fatty acids and as
a receptor for T2 bacteriophage [58]. Studies conducted in other Gram-negative bacteria have
shown that porin proteins can be used as potential vaccine candidates [59].
Several other proteins identified in our initial proteomic analysis merit brief mention with
regard to their potential use in vaccine studies. The OmpW protein is required for resistance to
phagocytosis and is protective against intraperitoneal infectious challenge with E. coli [60].
ClpX was shown to have potential use in a vaccine to protect against the nasopharyngeal colo-
nization of Streptococcus pneumoniae in mice [61]. OmpA is a major immunoreactive E. coli
outer membrane protein that has been studied for its role in bacterial invasion of brain micro-
vascular endothelial cells [62]. TibA is a 104 kDa outer membrane protein present on the tib
locus of the ETEC chromosome that contributes to ETEC invasion [63] and shares similarity
with several autotransporter adhesins of mucosal pathogens [4].
The three antigens we characterized in detail reduced the attachment of different ETEC
strains to HCT-8 cells, independent of their CF-type, and might thus be useful in future vaccine
preparations. The in vivo infectious challenge study with ETEC H10407 in mice showed that
all the antigens were protective. Mice immunized with ETEC_2479 showed the best protection
(88%), while mice immunized with Skp or MipA showed moderate protection (68 and 64%,
respectively). Mice that survived the infectious ETEC challenge had higher fecal IgA concentra-
tions, supporting the notion that the antigens elicited mucosal immune responses to prevent
bacterial colonization. The inverse relationship of bacterial loads in the lungs, as well as the
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survival of mice, correlated well with the fecal IgA levels, as mice that survived the challenge
had reduced ETEC loads, as compared with the mice that died.
Investigating ETEC intestinal colonization in mice requires pretreating the animals with
antibiotics to remove other bacteria and the exact mechanism by which ETEC colonize the
small intestine of mice is not fully understood [64]. One of the drawbacks of using the murine
intestinal model for ETEC challenge is that mice do not develop diarrhea even when they are
exposed to high doses of ETEC [21]. We were primarily interested in conducting survival
assays to determine the efficacy of our vaccine candidates. We therefore elected to use an intra-
nasal inoculation model. This model has been used previously as a model for enteric infections
[47, 48]. The mouse intestinal epithelium shares similarity to the bronchus of the lung, as the
lymphoid follicles present in the bronchial wall are similar to the Peyer’s patches of the intes-
tine. Mucosal immunity is an important protective mechanism, as attachment to mucosal sur-
faces is often the first step in establishing infection. This protection is mainly provided by
locally secreted sIgA, which neutralizes the pathogens at the point of infection [65]. If antigen
is delivered at the mucosal surface, it can induce a strong immune response in the locally asso-
ciated lymphoid tissue which, in turn, can travel to distal mucosal surfaces [66].
For vaccine development, it is important to target conserved antigens, yet, due to the diver-
sity in ETEC serotypes and the large number of CFs identified, it is difficult to choose any one
serotype-specific CF [67]. Finding broadly conserved, protective antigens is of primary impor-
tance. Our approach has resulted in finding three antigens that show heterologous protection
against a variety of ETEC strains that are diverse in CF type. Preliminary analysis of a panel of
89 strains isolated from Bangladesh showed that MipA, Skp, and ETEC_2479 were prevalent
in 89 (100%), 89 (100%), and 83 (93%) of the strains, respectively (D. Rasko, personal
communication).
However, a potential drawback also exists, as these antigens are conserved among other
pathogenic and commensal E. coli strains (Table 2), although the extent to which they are
expressed and surface-exposed in these other strains is unclear. The potential impact of using a
vaccine developed against antigens that are encoded by commensal organisms warrants further
investigation. Future studies could conceivably quantify the extent to which vaccination with
ETEC_2479, Skp, and MipA protect against other ETEC strains that have caused diarrheal dis-
ease in humans. Given the lack of full protection observed using each antigen independently,
an additional plan for future work is also to evaluate the efficacy of a cocktail of the three anti-
gens administered simultaneously.
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